News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
732,150 Results
Type
Article (49559)
Company Profile (299)
Press Release (682292)
Section
Business (217289)
Career Advice (3081)
Deals (36810)
Drug Delivery (96)
Drug Development (84097)
Employer Resources (181)
FDA (16930)
Job Trends (15886)
News (365585)
Policy (35008)
Tag
Academia (2810)
Africa (943)
Alliances (53101)
Alzheimer's disease (1210)
Approvals (16856)
Arizona (190)
Artificial intelligence (98)
Asia (40875)
Australia (6772)
Bankruptcy (359)
Best Places to Work (11976)
Biotechnology (210)
Breast cancer (80)
C2C Services and Suppliers (85260)
California (2179)
Canada (1019)
Cancer (654)
Career advice (2592)
Cell therapy (163)
China (172)
Clinical research (65919)
Collaboration (206)
Colorado (91)
Compensation (115)
Connecticut (96)
COVID-19 (2657)
Cystic fibrosis (81)
Data (482)
Diabetes (101)
Diagnostics (6362)
Drug pricing (87)
Earnings (88036)
Employer resources (156)
Europe (90539)
Events (116430)
Executive appointments (194)
FDA (17245)
Florida (315)
Funding (194)
Gene therapy (116)
Georgia (72)
GLP-1 (575)
Government (4715)
Healthcare (20107)
Hotbed/Location (505396)
Illinois (307)
Indiana (161)
Infectious disease (2700)
Inflammatory bowel disease (100)
Interviews (541)
IPO (16627)
Job creations (4112)
Job search strategy (2200)
Kansas (96)
Layoffs (438)
Legal (8632)
Lung cancer (126)
Manufacturing (120)
Maryland (457)
Massachusetts (1805)
Medical device (13794)
Medtech (13799)
Mergers & acquisitions (20099)
Metabolic disorders (307)
Michigan (137)
Minnesota (232)
Neuroscience (1405)
New Jersey (674)
New York (683)
NextGen Class of 2024 (7133)
Non-profit (4948)
North Carolina (679)
Northern California (941)
Obesity (185)
Ohio (119)
Opinion (215)
Patents (83)
Pennsylvania (638)
People (59778)
Phase I (20327)
Phase II (28877)
Phase III (21825)
Pipeline (144)
Policy (72)
Postmarket research (2831)
Preclinical (8759)
Radiopharmaceuticals (245)
Rare diseases (159)
Real estate (6368)
Regulatory (22753)
Research institute (2498)
Resumes & cover letters (483)
South America (1338)
Southern California (876)
Startups (3813)
Texas (285)
United States (9856)
Vaccines (538)
Washington State (271)
Weight loss (157)
Date
Today (32)
Last 7 days (685)
Last 30 days (2667)
Last 365 days (37984)
2024 (28562)
2023 (41484)
2022 (52742)
2021 (57532)
2020 (56438)
2019 (49686)
2018 (37677)
2017 (34261)
2016 (34300)
2015 (40228)
2014 (34329)
2013 (29773)
2012 (31758)
2011 (32094)
2010 (30606)
732,150 Results for "johnson and johnson vision care inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Proteologix, Inc. to be Acquired by Johnson & Johnson
Proteologix, Inc., a privately-held biotechnology company focused on bispecific antibodies for immune-mediated diseases, today announced that it has entered into a definitive agreement to be acquired by Johnson & Johnson
May 16, 2024
·
2 min read
Press Releases
Johnson & Johnson Rolls Out New TECNIS Odyssey Next-Generation Intraocular Lens Offering Cataract Patients Precise Vision at Every Distance in Any Lighting
September 30, 2024
·
13 min read
Deals
Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment
Acquisition advances Johnson & Johnson’s leading Dermatology portfolio with opportunity to address significant unmet need in atopic dermatitis (AD).
May 16, 2024
·
8 min read
Deals
Johnson & Johnson Completes Acquisition of Shockwave Medical
Johnson & Johnson announced it has completed its acquisition of Shockwave Medical. Shockwave is now part of Johnson & Johnson and will operate as a business unit within Johnson & Johnson MedTech.
May 31, 2024
·
5 min read
Pharm Country
Johnson & Johnson Highlights Commitment to Transform Treatment of Retinal Diseases at ARVO 2024
Johnson & Johnson today announced that eight company-sponsored presentations will be featured during the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting taking place in Seattle from May 5–9, 2024.
May 3, 2024
·
8 min read
Job Trends
Johnson & Johnson to Participate in the BofA Securities Health Care Conference
Johnson & Johnson (NYSE: JNJ) will participate in the BofA Securities Health Care Conference on Tuesday, May 14th, at the Encore Hotel, Las Vegas, Nevada. John Reed, Executive Vice President, Innovative Medicine, R&D, will represent the Company in a session scheduled at 4:40 pm (Eastern Time).
April 2, 2024
·
1 min read
Deals
Johnson & Johnson to Acquire Shockwave Medical
Johnson & Johnson and Shockwave Medical, Inc. announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Shockwave for $335.00 per share in cash, corresponding to an enterprise value of approximately $13.1 billion including cash acquired.
April 5, 2024
·
15 min read
Business
Johnson & Johnson Reports Q1 2024 Results
Johnson & Johnson announced results for first-quarter 2024. “Johnson & Johnson’s solid first quarter performance reflects our sharpened focus and the progress in our portfolio and pipeline,” said Joaquin Duato, Chairman and Chief Executive Officer.
April 16, 2024
·
29 min read
Pharm Country
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn’s disease
Johnson & Johnson (NYSE: JNJ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of TREMFYA® (guselkumab) for the treatment of adults with moderately to severely active Crohn’s disease.
June 20, 2024
·
21 min read
Biotech Beach
Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation Challenge
Artelo Biosciences, Inc. today announced its selection as a finalist in Johnson & Johnson’s Innovation Challenge.
March 12, 2024
·
4 min read
1 of 73,215
Next
